- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06507787
Evaluación del impacto del análisis de sangre EDIT-B® en el estado de salud de pacientes que presentan un episodio depresivo mayor. Utilidad clínica y aspectos médico-económicos (SEM EDIT-B)
Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior. The Diagnostic and Statistical Manual of Mental Disorders (DSM) defines a Major Depressive Episode (MDE) by a combination of at least five different symptoms, with at least one depressed mood or loss of interest. MDEs can occur in isolation or as part of Major Depressive Disorder (MDD) or bipolar disorder (BD). Bipolar disorders affect 2% of the world's population and are defined by episodes of mania (Type I BD) or hypomania (Type II BD) alternating with episodes of depression and periods of remission.
Depression occurring whether in the context of BD or MDD is defined with the same clinical criteria. However, the pharmacological treatments are different in the two groups. In particular, antidepressants prescribed without a thymoregulator in bipolar patients can lead to a worsening of the episode, favoring suicidal behavior or a manic turn.
The average interval between the onset of BD symptoms and appropriate diagnosis is estimated to be approximately 7 years, which delays appropriate management and treatment and increases the risk of suicide.
Biological markers able to differentiate between the different types of depression were lacking before the advent of EDIT-B®; one of the main objectives of this research is to measure the clinical impact of the use of EDIT-B® in the short and medium term on the management of patients with BD and major depression. The health economic aspect will also be considered.
In total, 450 patients in two different groups (EDIT-B® group and control group) will be recruited over a study timeline of 24 months. Study participation is over 6 months with 4 visits.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Benjamin Dubuc
- Correo electrónico: benjamin.dubuc@alcediag-alcen.com
Copia de seguridad de contactos de estudio
- Nombre: Mary Menhem, PharmD, MSc
- Número de teléfono: +33788970700
- Correo electrónico: mary.menhem@alcediag-alcen.com
Ubicaciones de estudio
-
-
-
Erstein, Francia
- Aún no reclutando
- CH Erstein
-
Contacto:
- Geraldine Pfleger, Dr
- Número de teléfono: +33 3 90 64 21 46
- Correo electrónico: geraldine.pfleger@ch-erstein.fr
-
Investigador principal:
- Geraldine Pfleger, Dr
-
Issy-les-Moulineaux, Francia
- Aún no reclutando
- AP-HP Corentin Celton
-
Contacto:
- Nicolas Hoertel, Pr
- Número de teléfono: +33 1 58 00 44 21
- Correo electrónico: nicolas.hoertel@aphp.fr
-
Investigador principal:
- Nicolas Hoertel, Pr
-
La Roche-sur-Foron, Francia
- Aún no reclutando
- Etablissement Public de Santé Mentale (EPSM) 74
-
Contacto:
- Rocco De Filippis, Pr
- Número de teléfono: +33 749121443
- Correo electrónico: defilippis-r@ch-epsm74.fr
-
Investigador principal:
- Rocco De Filippis, Pr
-
Lyon, Francia
- Reclutamiento
- Clinique Villa des Roses
-
Contacto:
- Pascal Frilloux, Dr
- Número de teléfono: +33 4 78 15 00 00
- Correo electrónico: pascal.frilloux-ext@inicea.fr
-
Investigador principal:
- Pascal Frilloux, Dr
-
Montrond-les-Bains, Francia
- Reclutamiento
- Clinique Le Clos Montaigne
-
Contacto:
- Christophe Aimo, Dr
- Número de teléfono: +33 4 77 36 01 00
- Correo electrónico: christophe.aimo@inicea.fr
-
Investigador principal:
- Christophe Aimo, Dr
-
Paris, Francia
- Reclutamiento
- GHU Paris Psychiatrie et Neurosciences
-
Contacto:
- Juan Zambrano
- Número de teléfono: +33145658153
- Correo electrónico: juan.zambrano@ghu-paris.fr
-
Investigador principal:
- Chantal Henry, Pr
-
Ville-d'Avray, Francia
- Aún no reclutando
- Clinique Médicale de Ville d'Avray
-
Contacto:
- Jérôme Dischamps
- Número de teléfono: +33147094314
- Correo electrónico: jdischamps@wanadoo.fr
-
Investigador principal:
- Jérôme Dischamps
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patients with a MDE, moderate to severe (DSM V criteria and MADRS score ≥19)
-
Age between 18 and 65 years, gender indifferent
-
Benefitting from health insurance coverage
-
Having signed an informed consent and agreed to follow the study protocol to completion
-
Patients for whom there is doubt regarding a bipolar disorder diagnosis, and/or presenting one or more of the following criteria:
- More than 3 episodes of MDE in personal medical history
- Psychotic symptoms
- Family history of bipolar disorder
- Onset of the first MDE before the age of 25
- Atypical symptoms or mixed features during depressive episodes
- Addiction
- Personal history of suicide attempts
- Resistance to antidepressants
- Postpartum depression within 6 months of birth
Exclusion Criteria:
- Depression in the context of schizophrenia or autism spectrum disorder
- Patient with a well-established diagnosis of bipolar disorder
- Patients who is already receiving a mood stabilizer
- Severe somatic diseases that may interfere with the follow-up or associated with treatments at risk of secondary manic decompensation
- Neurodegenerative diseases
- Pregnant women
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: With EDIT-B test result
The investigator will have the EDIT-B® test result to guide the treatment strategy. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
|
Comparador de placebos: Without EDIT-B test result
The investigator will not have the EDIT-B® test result, but EDIT-B® is still performed on participants in the beginning of the study. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Improvement in depressive symptoms between inclusion and 15-16 weeks visit.
Periodo de tiempo: 4 months (from inclusion visit to 15-16 weeks visit)
|
Clinically meaningful improvement at week 15-16 in depressive symptoms, defined as a 6-point or greater reduction in MADRS total score from baseline, without a manic switch, defined as an increase in the YMRS total score above 11 from baseline, measured using a composite endpoint. |
4 months (from inclusion visit to 15-16 weeks visit)
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SEM EDIT-B
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .